Report on Management of Renal Failure in Europe, XXIV, 1993

Valderrábano, Fernando; Jones, Elizabeth H.; Mallick, N. P.

doi:10.1093/ndt/10.supp5.1

Cited by 305 publications

(81 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was taken from the patients' hospital records and coded according to the European Dialysis and Transplant Association (EDTA) classification, 17 which consists of 65 different codes (assigned between 0 and 99). The individual classifications were grouped in order to simplify the presentation of data.…”

Section: Cause Of Esrd (Clinical Questionnaire)mentioning

confidence: 99%

An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales

Roderick

Nicholson²,

Armitage³

et al. 2005

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, ...

show abstract

Section: Cause Of Esrd (Clinical Questionnaire)mentioning

confidence: 99%

An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales

Roderick

Nicholson²,

Armitage³

et al. 2005

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Further, the CV mortality in ESRD patients has been reported to be 10–20 times higher than that of the general population [2]. The high CV mortality rate in ESRD patients is likely to be attributed to a higher prevalence of certain traditional risk factors and other causes that are unique to the ESRD population.…”

Section: Introductionmentioning

confidence: 99%

Familiality of Cardiovascular Mortality in End-Stage Renal Disease Patients

Naiman¹,

Cheung²,

Goldfarb–Rumyantzev³

2008

Am J Nephrol

View full text Add to dashboard Cite

A very high rate of cardiovascular (CV) death is well recognized in individuals with end-stage renal disease (ESRD). Besides many other factors, this excess risk may also be related to familiality. We tested this hypothesis by estimating the risk of CV death among both ESRD patients and their relatives. In this case-control study, we used the Utah Population Database (UPDB), which includes genealogy records, state-wide death certificates as well as other data sets. These have been linked to the University of Utah Health Sciences Enterprise Data Warehouse which provides multiple diagnosis data sources. Patients with ESRD either on dialysis or who received a kidney transplant were identified in the clinical databases at the University of Utah Dialysis Program and Kidney Transplant Program or from Utah death certificates. CV deaths were identified by the reporting on the death certificates. The relative risks for CV death, adjusted for several potential confounders in the ESRD patients (n = 516) and in their first-degree (n = 2,418) and second-degree (n = 7,720) relatives were estimated in relation to the general population. Using information from death certificates, ESRD patients were found to have disproportionately increased risk for CV mortality (relative risk or RR = 2.4; 95% CI 2.11–2.72), compared to the general population. First-degree relatives of ESRD patients were also found to have an increased CV mortality risk (RR = 1.10; 95% CI 1.01–1.20). When the specific categories of CVD were analyzed, the first-degree relatives also had higher risks for death from acute myocardial infarction (RR = 1.20; 95% CI 1.03–1.40) or heart failure (RR = 1.32; 95% CI 1.12–1.56). An increased risk for CV mortality was, however, not observed in second-degree relatives of ESRD patients, except for the subcategory of hypertensive heart disease (RR = 1.24, 95% CI 1.01–1.49). In conclusion, this study suggests that, in addition to many putative risk factors, the increased risk of CV death in ESRD patients may have a familial contribution.

show abstract

“…The 1993 EDTA report on management of renal failure [2] shows a low incidence of renal amyloidosis in Europe (~1%) in 1992. However, in some countries of Correspondence and offprint requests to: Professor F. P. Schena, Institute of Nephrology-Polyclinic, Piazza G. Cesare 11, 70124 Bari, Italy.…”

Section: Introductionmentioning

confidence: 99%

Clinical and therapeutic aspects of renal amyloidosis

Schena

Pannarale

Carbonara

1996

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Abstract. Renal amyloidosis is not a frequent disease: its annual frequency is ~2.5-2.8% of all renal biopsies. Individual cases are normally rare and for this reason clinical findings and therapeutic results obtained by clinical multicentre studies are well considered. This review describes the clinical and therapeutic aspects of renal amyloidosis and refers particularly to the results obtained by the Italian Study Group for renal amyloidosis and by the multicentre Italian study protocol for AL amyloidosis.

show abstract

Report on Management of Renal Failure in Europe, XXIV, 1993

Cited by 305 publications

References 0 publications

An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales

An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales

Familiality of Cardiovascular Mortality in End-Stage Renal Disease Patients

Clinical and therapeutic aspects of renal amyloidosis

Contact Info

Product

Resources

About